Creo Medical Group, a medical device company focused on the emerging field of surgical endoscopy, has extended its distribution agreement with Hoya Group, Pentax Medical (Pentax) for the Asia-Pacific (APAC) region.
Image: Creo Medical Group signs agreement with Pentax Medical. Photo: Courtesy of patrisyu/FreeDigitalPhotos.net.
Under the terms of the original distribution agreement, Creo granted Pentax the right to distribute Creo’s Speedboat product and CROMA platform in the Asia Pacific region for five years subject to agreement of final terms by territory.
The addendum further entrenches Creo’s relationship with Pentax with firm commitment to roll out to various territories in conjunction with establishing Creo’s Clinical Education Program and thereafter seeding the chosen markets.
Australia will be the first Asia Pacific territory in which Pentax will establish Creo’s Clinical Education Program and subsequently seed the market. Pentax will purchase a minimum quantity of CROMA advance energy platforms and Speedboat instruments with the first products expected to be shipped within three months.
Furthermore, Creo has agreed to extend the term of Pentax’s distribution rights in each territory in which Pentax establishes Creo’s Clinical Education Programme for a period of five years from the date on which Creo’s products are registered in such territory.
Creo has commenced the regulatory registration process for its products in Australia and in conjunction with Pentax Creo has begun introducing doctors from Australia and other territories to the clinical education program here in Europe which will be rolled out into APAC in the coming months.
CROMA’s electrosurgical platform combines bipolar radiofrequency for precise localised cutting and microwave for controlled coagulation. Speedboat is the first product approved in a suite of tools under development to aid the endoscopist in minimally invasive surgery.
The Speedboat device helps reduce the risks associated with alternative laparoscopic procedures, reducing the length of hospital stays and transferring therapy from the operating room to the endoscopy room.
Creo Medical Group CEO Craig Gulliford said: “The extension of our agreement with Pentax marks a significant milestone in the commercialisation of Speedboat, our lead product. Creo is dedicated to improving patient outcomes and helping clinicians by bringing advanced energy to the emerging field of surgical endoscopy.
“Speedboat is paving the way for our suite of GI devices under development. Our products are rapidly gaining traction in the endoscopic field and with Pentax as our partner in the Asia Pacific region, their expertise and knowledge will prove invaluable to Creo in these important markets and as we build our reputation worldwide.”
Pentax Americas president and CEO and M&A director David Woods said: “As a leading supplier of innovative and advanced medical products for minimally invasive procedures we recognise the great potential of the CROMA platform and Speedboat.
“I am pleased that we have been able to deepen our relationship with Creo. Ultimately, under this expanded commercial agreement more patients will benefit from the power of precise cutting and controlled coagulation, leading to better clinical outcomes in an outpatient setting.”
Source: Company Press Release